Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Operating Leases (2022 - 2023)

Candel Therapeutics' Operating Leases history spans 2 years, with the latest figure at $1.1 million for Q3 2023.

  • For Q3 2023, Operating Leases fell 31.16% year-over-year to $1.1 million; the TTM value through Sep 2023 reached $1.1 million, down 31.16%, while the annual FY2022 figure was $1.5 million, N/A changed from the prior year.
  • Operating Leases for Q3 2023 was $1.1 million at Candel Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $1.8 million in Q1 2022 and bottomed at $1.1 million in Q3 2023.